News from bausch health companies inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 12, 2022, 08:00 ET SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION

Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today released the...

Oct 05, 2022, 08:00 ET Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") is continuing its commitment to improving lives with the announcement of modifications ...

Oct 03, 2022, 08:00 ET SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Sep 28, 2022, 08:09 ET Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the final results and expiration of its previously announced offers (the ...

Sep 14, 2022, 09:00 ET Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations

Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the results to date of its previously announced offers (the "Exchange...

Sep 09, 2022, 07:00 ET Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("the Company"), and its gastroenterology business Salix Pharmaceuticals, today responded to the U.S....

Sep 08, 2022, 16:45 ET Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations

Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") clarified today certain provisions related to its previously announced offers (the...

Aug 30, 2022, 23:28 ET Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes

Bausch Health Companies Inc. (NYSE/TSX: BHC) ( "Company") announced today that it has commenced offers (the "Exchange Offers") to exchange the...

Aug 22, 2022, 07:00 ET Bausch Health Continuing Process Toward Separating Bausch + Lomb

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") has transferred common shares in an amount equal to approximately...

Aug 10, 2022, 18:00 ET Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the...

Aug 10, 2022, 07:00 ET Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Aug 09, 2022, 07:00 ET BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second-quarter 2022 financial...

Jul 28, 2022, 15:45 ET Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation

Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of...

Jul 27, 2022, 19:35 ET Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter financial results on Tuesday, Aug. 9, 2022. Bausch...

Jul 13, 2022, 07:00 ET Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Jun 23, 2022, 16:54 ET Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the results of its 2022 annual meeting of...

Jun 21, 2022, 07:00 ET Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the Company is providing a presentation on its...

Jun 20, 2022, 07:00 ET Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Jun 16, 2022, 17:30 ET Bausch Health Provides Update on Solta Medical

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced an update on its previously stated plan to pursue an...

May 18, 2022, 07:00 ET Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

May 11, 2022, 07:00 ET Bausch Health Announces Participation In Upcoming Investor Conferences

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in several upcoming ...

May 10, 2022, 06:59 ET Bausch Health Companies Inc. Announces First-Quarter 2022 Results

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its first-quarter 2022 financial results....

May 06, 2022, 12:08 ET Bausch Health Announces Thomas J. Appio As Chief Executive Officer

Bausch Health Companies Inc. (NYSE/TSX: BHC) (Bausch Health) today announced its full leadership team and Board of Directors, including Chief...

May 03, 2022, 06:59 ET Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novaliq GmbH, a...

Apr 29, 2022, 07:00 ET Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its first-quarter financial results on Tuesday, May 10, 2022. Bausch...